RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Abstract Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer....

Full description

Bibliographic Details
Main Authors: Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría, Chiara Ambrogio
Format: Article
Language:English
Published: Nature Portfolio 2024-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-51828-2

Internet

https://doi.org/10.1038/s41467-024-51828-2

Similar Items